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ABSTRACT 
Objective: The objective of the present study is to develop a stability-indicating reverse-phase high-performance liquid chromatography (RP-HPLC) 
method for qualitative and quantitative determination of Eptifibatide and its impurities in bulk and pharmaceutical dosage forms.  
Methods: The chromatographic separation was carried on Phenomenex Luna C18 column (250 mm×4.6 mm; 5µ id) as stationary phase, methanol 
and phosphate buffer at pH 6.4 in the ratio of 65:45 (v/v) as mobile phase at flow rate of 1.0 ml/min, Ultra Violet (UV) detection was carried at the 
wavelength of 236 nm and the analysis was completed with a run time of 15 min.  
Results: In the developed conditions, the retention time of Eptifibatide and its impurities 1 and 2 were found to be 3.35, 4.93 and 8.18 min, 
respectively. The method was validated for system suitability, range of analysis, precision, specificity, stability and robustness. Spiked recovery at 
50%, 100% and 150% was carried for both standard and impurities and the acceptable % recovery of 98-102 was observed for Eptifibatide and 
both impurities studied and the % Relative standard deviation (RSD) in each spiked level was found to be less than 2. Stability tests were done 
through the exposure of the analyte solution to five different stress conditions i. e expose to 1N Hydrochloric acid (HCl), 1 N Sodium hydroxide 
(NaOH), 3% Hydrogen peroxide (H2O2
Conclusion: The developed method was found to be suitable for the quantification of Eptifibatide and can separate and analyse impurities 1 and 2.  
), 80 °C temperature to UV radiation. In all the degradation conditions, standard drug Eptifibatide was 
detected along with both the impurities studied and the degradation products were successfully separated. In the formulation analysis, there is no 
other chromatographic detection of other impurities and formulation excipients.  
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INTRODUCTION 
Eptifibatide is an antiplatelet drug and a disulfide-linked cyclic 
peptide and a short-acting reversible inhibitor of platelet 
aggregation [1]. It is used for the treatment of myocardial infarction, 
acute coronary syndrome, intracoronary stenting and for patients 
undergoing percutaneous coronary intervention [2]. The enhanced 
antiplatelet or thrombosis effect of Eptifibatide is usually coupled 
with naturally accompanying aspirin and/or heparin therapy [3]. 
The molecular structure of Eptifibatide was given in fig. 1.  
 
 
Fig. 1: Molecular structure of eptifibatide 
 
The reversible inhibition platelet aggregation of Eptifibatide is by 
preventing the binding of fibrinogen, von Wille brand factor, and 
other adhesive ligands to glycoprotein IIb/IIIa. The platelet 
aggregation of Eptifibatide depends on the concentration and dosage 
of administration [4]. Eptifibatide contains a KGD (lysine–glycine–
aspartic acid) sequence similar to that found in the rattlesnake 
(Sistrurus miliarius barbouri) venom barbourin. This sequence is 
purported to selectively block the platelet glycoprotein IIb–IIIa 
complex without affecting the functions of other integrins [5]. 
Bleeding, hypotension, cardiovascular failure, serious arrhythmias 
are the possible side effects of Eptifibatide, whereas the 
thrombocytopenia, chest pain, bradycardia, angioedema and 
hypotension are observed in the patients with overdose [6]. 
The literature survey for the available analytical methods for the 
estimation of Eptifibatide confirms that two HPLC [7, 8] and one 
UV spectrophotometer [9] assay methods reported for the 
estimation of Eptifibatide in pharmaceutical formulations. One 
Spectrofluorimetry method was reported for the estimation of 
Eptifibatide in formulations and human plasma [10]. The 
characterization using stability study of Eptifibatide was 
reported using Liquid chromatography-mass spectrometry 
(LCMS) analysis method [11]. One ultra-performance liquid 
chromatography (UPLC) method reported for the estimation of 
Eptifibatide in the presence of its one impurity was reported 
[12]. The literature survey reveals that no analytical method 
reported for the estimation of Eptifibatide and its impurities in 
pharmaceutical formulations using HPLC. There are ten 
impurities were officially identified for Eptifibatide, but 
impurities 1 and 2 only available to the authors. Hence the 
presence study aimed to develop a simple HPLC method for the 
estimation of Eptifibatide and its impurities 1 and 2 in bulk drug 
and formulations. The molecular structure of impurities studied 
was given in fig. 2. 
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Impurity 1    Impurity 2 
Fig. 2: Molecular structure of eptifibatide impurities in the study 
 
MATERIALS AND METHODS 
Reagents 
The working standard drug Eptifibatide (99.03% purity) and its 
Impurities studied were obtained from Samarth Life Sciences PVT. 
LTD, Mumbai, Maharashtra. Methanol (HPLC Grade) and Acetonitrile 
(HPLC grade) were purchased from Merck chemicals, Mumbai. Ultra-
Pure (Milli-Q®
Instrumentation 
) Water was used during the study. All the other 
chemicals used during the study are of analytical reagent grade and 
were purchased from Merck chemicals, Mumbai. 
HPLC studies were carried on Agilent (USA) 1100 series HPLC 
instrument coupled with Quaternary pump (G1311 A), Thermostatic 
autosampler (G 1329A) with an injection volume of 0. 1–1500 µl and 
programmable UV detector (G 1314 A). Agilent chem. station LC 
software was used for integrating the chromatograms.  
Preparation of solutions 
pH 6.8 phosphate buffer solution 
Buffer solution was prepared by mixing of Sodium phosphate dibasic 
heptahydrate (3.121 g) and Sodium phosphate monobasic 
monohydrate (7.044 g) in 1000 ml HPLC grade water and the pH of 
was adjusted to 6.8 using 0.1 N hydrochloric acid.  
Standard drug and impurity solutions 
A stock solution of 1 mg/ml was prepared for both standard and 
impurities separately by accurately weighing 50 mg of compound 
and was dissolved in 50 ml of Methanol. Required dilutions for were 
prepared from the stock solution and from the prepared dilutions, 
10 ml of selected concentrations of Eptifibatide, Impurity 1 and 2 
were mixed separately and the mixture solution was used for 
method development and validation studies [13, 14]. 
Formulation solution 
Opened five vials of Eptifibatide with brand Eptifab®
Method development [15-18] 
 (20 mg/10 ml) 
(each vial contains Eptifibatide: 20 mg/10 ml) and pooled the 
content of each individual vial into a clean and dried 50 ml 
volumetric flask and mix uniformly. Then 10 ml was accurately 
separated and was made up to the mark in a 100 ml volumetric flask. 
Filter the content and diluted to standard concentration and was 
used for the assay.  
UV-visible spectrophotometer was used for the determination of 
suitable UV absorption wavelength for Eptifibatide and its 
impurities. The wavelength maxima of Eptifibatide and its impurities 
were determined at a concentration of 10 µg/ml. The overlay UV 
absorption spectra of Eptifibatide and its impurities confirm the 
suitable wavelength for the detection of Eptifibatide and its 
impurities in HPLC.  
Different types of stationary phase like ProntoSIL Hypersorb ODS 
C18 column, Waters RP-C 18 column and Phenomenex Luna C18 
columns of 150 mm and 250 mm was studied was optimised 
separation of Eptifibatide and its impurities. The mobile phase 
composition with different solvents like methanol and acetonitrile in 
combination with different pH buffers was studied. Based on the 
separation of Eptifibatide and its impurities, the mobile phase was 
optimised. The flow rate of the mobile phase was also optimised in 
the range of 0.7 to 1.2 ml/min. The optimised conditions that 
produce best separation of Eptifibatide and its impurities were 
confirmed and proceed for further validation.  
Method validation 
The method developed for the analysis of Eptifibatide and its 
impurities was validated as per the available literature and ICH 
guidelines [19-25].  
System suitability 
Freshly prepared standard solution at a recovery level of 
Eptifibatide and its impurities was analyzed in the developed 
method. The system suitability was evaluated by summarizing the 
parameters such as relative response factor (RRF), relative retention 
time (RRT), asymmetric factor (tail factor) and plate count (number 
of theoretical plates).  
Linearity and range 
Standard solution at a concentration rage of 50–1000 µg/ml of 
Eptifibatide and 0.5–10µg/ml of both the impurities were prepared 
and analysed in the method. The calibration curve was plotted by 
taking concentration prepared on X-axis and peak area obtained on 
Y-axis.  
Precision 
Intraday and interday precision studies have performed by 
analysing the standard solution containing Eptifibatide and its 
impurities six times in the same day for intraday precision and six 
times in three different days for interday precision. The % relative 
standard deviation (RSD) of the peak area was calculated and the % 
RSD of<2 was considered as acceptable.  
Ruggedness 
The standard solution was analysed six times in the same day with a 
change in the analyst was performed for the evaluation of the 
ruggedness of the method. The % RSD of peak area obtained for 
standard and impurities was calculated separately and the % RSD 
of<2 was considered as the method is rugged.  
Robustness 
The influence of small changes in the developed conditions for the 
analysis of Eptifibatide and its impurities have been determined in a 
robustness study. In this change in mobile phase composition (±5 ml 
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of organic modifier), detector wavelength (±5 nano meters (nm)) 
and pH of the mobile phase (±0.1 factor) have been studied. In each 
changed condition, the % change compared with optimised 
condition was calculated for both impurities and Eptifibatide and a 
% change of <2 was considered as acceptable as per guidelines.  
Recovery 
In recovery/accuracy study, 50 %, 100 % and 150 % spiked levels of 
known standard concentration (100 %) in the calibration range was 
performed and the % recovery was calculated in each spiked level 
by comparing with calibration results. The % recovery of 98-102 
was considered as acceptable. 
Force degradation studies 
50 mg of standard drug Eptifibatide was mixed with 50 ml of 0.1 N 
HCl, 0.1 N NaOH and 3 % H2O2
Formulation analysis 
 solution separately for 24 h in acidic, 
basic and oxidative degradation study. Then the solution was 
neutralised and diluted to standard concentration. 50 mg of 
standard drug Eptifibatide was kept in an air oven at 60 °C for 24 h 
in thermal degradation study and kept under UV light at 254 nm for 
24 h for photolytic degradation study. Then it was diluted to 
standard concentration and the degradation solutions were analysed 
in the developed method. The number of degradation compounds 
formed and the % degradation was calculated by comparing with 
unstressed results of Eptifibatide.  
The formulation solution of Eptifibatide with brand Eptifab® 
RESULTS 
was 
analysed in the developed method. The % assay was calculated by 
comparing the formulation results with calibration curve results.  
The initial method development trails were performed using acetate 
buffer as pH modifier and methanol and acetonitrile in different 
compositions as organic modifier. The utilization of acetate buffer in 
the mobile phase gives poor resolution of impurities and the peak 
area response was found to be very less. The replacing the acetate 
buffer with phosphate buffer produces better resolution and 
response of both impurities and Eptifibatide. The column length 
with 150 mm produces poor resolution between the impurities and 
Eptifibatide and hence the column length with 250 mm was 
confirmed as stationary phase. The systematic trails of method 
development for the separation of Eptifibatide and its impurities 
with acceptable system suitability was achieved using Phenomenex 
Luna C18 column (250 mm×4.6 mm; 5µ id) as stationary phase, 
methanol and phosphate buffer at pH 6.4 in the ratio of 65:45 (v/v) 
as mobile phase at a flow rate of 1.0 ml/min, UV detection was 
carried at wavelength of 236 nm and the analysis was completed 
with a run time of 15 min. In these conditions, acceptable system 
suitability was observed for both impurities and Eptifibatide (fig. 3). 
  
 
Fig. 3: Optimised chromatogram of Eptifibatide, impurity 1 and 2 
 
In the developed method conditions, the system suitability parameters 
like RRF, RRT, tail factor and number of theoretical plates were found 
to be within the acceptable limit (table 1) for Eptifibatide and its 
impurities studied confirms that the method is suitable. 
  
Table 1: System suitability results 









Eptifibatide 225 4.9341±0.003 --- --- 4591 1.01 5.61 
300 4.9336±0.001 --- --- 4604 1.02 5.59 
375 4.9328±0.004 --- --- 4576 1.01 5.66 
Impurity 1 1.5 8.1883±0.004 0.6789±0.004 0.058±0.003 6756 0.89 13.87 
2 8.1871±0.003 0.6810±0.004 0.066±0.001 6582 0.83 13.81 
2.5 8.1891±0.005 0.6803±0.001 0.069±0.001 6659 0.85 13.79 
Impurity 2 1.5 3.3580±0.003 1.6595±0.002 0.091±0.001 9809 0.97 --- 
2 3.3598±0.001 1.6594±0.003 0.091±0.006 9912 0.99 --- 
2.5 3.3561±0.004 1.6602±0.002 0.090±0.002 9875 0.95 --- 
#
 
Values given in table is the average±standard deviation of three replicate experiments 
The linearity was observed within the concentration range of 75–
540 µg/ml for Eptifibatide and 0.5–3 µg/ml for both impurity 1 and 
2. The calibration curve was found to be linear with a very high 
correlation coefficient for both impurities and standard Eptifibatide. 
Linearity results were given in table 2 and the calibration curve was 
shown in fig. 4, 5 and 6 for Eptifibatide, imp A and B, respectively. 
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Table 2: Linearity results 
S. No. Eptifibatide Impurity 1 Impurity 2 
Concentration in µg/ml Peak area Concentration in µg/ml Peak area Concentration in µg/ml Peak area 
1 75 323112 0.5 18118 0.5 29223 
2 150 589993 1 35602 1 54104 
3 225 818630 1.5 54756 1.5 77885 
4 300 1136746 2 74987 2 98494 
5 375 1364363 2.5 92949 2.5 121067 
6 450 1628540 3 112379 3 149014 
 
 
Fig. 4: Linear calibration curve for Eptifibatide 
 
 
Fig. 5: Linear calibration curve for imp 1 
 
 
Fig. 6: Linear calibration curve for imp 2 
 
Precision was carried for the standard solution containing 300 
µg/ml of Eptifibatide and 2.0 µg/ml of impurity 1 and 2. The % RSD 
of peak area response was found to be 0.16, 0.30 and 0.22 in 
intraday precision, 0.35, 0.57 and 0.73 in interday precision and 
0.48, 0.22 and 1.37 in ruggedness respectively for Eptifibatide, 
impurity 1 and 2 respectively. Hence the method developed for the 
analysis of Eptifibatide and its impurities was found to be rugged 
and precise.  
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The % change in all the changed conditions in robustness study was 
found to be with the acceptable limit of less than 2 (table 3) for 
Eptifibatide and its impurities studied. This confirms that the 
method is found to be robust as there is no considerable change in 
the separation and detection of Eptifibatide and impurities when a 
small change in the developed method conditions. 
Accuracy of the method was determined spiked recovery studies by 
spiking 50%, 100% and 150% concentrations of target 150 µg/ml for 
Eptifibatide, 1.0 µg/ml for impurity 1 and 2. The % recovery in was 
calculated for both standard and impurities in each analysis and the % 
RSD was calculated for each spiked level. The acceptable % recovery of 
98-102 was observed for Eptifibatide and both impurities studied and 
the % RSD in each spiked level was found to be less than 2 (table 4) 
which is the acceptable limit. Hence the method was found to be 
accurate. Accuracy of the method was determined spiked recovery 
studies by spiking 50%, 100% and 150% concentrations of target 150 
µg/ml for Eptifibatide, 1.5 µg/ml for impurity 1 and 2. The % recovery 
in was calculated for both standard and impurities in each analysis and 
the % RSD was calculated for each spiked level. The acceptable % 
recovery of 98-102 was observed for Eptifibatide and both impurities 
studied and the % RSD in each spiked level was found to be less than 2 
(table 4), which is the acceptable limit. Hence the method was found to 
be accurate. 
  
Table 3: Robustness results 
S. No. Changed 
condition 
Eptifibatide Impurity 1 Impurity 2 
Peak area % Change Peak area % Change Peak area % Change 
1 Standard 1136746 --- 74268 --- 98770 --- 
2 MP 1 1129280 0.66 74268 0.96 98770 0.28 
3 MP 2 1127593 0.81 74941 0.06 97740 0.77 
4 pH 1 1138965 0.20 75161 0.23 98286 0.21 
5 pH 2 1126817 0.87 74645 0.46 99221 0.74 
6 WL 1 1142131 0.47 73986 1.33 99413 0.93 
7 WL 2 1127792 0.79 74440 0.73 99146 0.66 
MP (Mobile Phase) 1: methanol and phosphate buffer in the ratio of 60:40 (v/v), MP 2: methanol and phosphate buffer in the ratio of 70:30 (v/v); 
WL (Wavelength) 1: 241 nm, WL 2: 231 nm; pH 1: 6.3, pH 2: 6.5;  
 









% RSD of 
recovery Target Spiked Final 
1 50% Eptifibatide 150 75 225 224.22±0.299 99.653±0.133 0.133 
2 Impurity 1 1 0.5 1.5 1.482±0.004 98.800±0.291 0.294 
3 Impurity 2 1 0.5 1.5 1.491±0.006 99.400±0.367 0.369 
4 100% Eptifibatide 150 150 300 298.043±0.519 99.348±0.173 0.174 
5 Impurity 1 1 1 2 1.979±0.011 98.950±0.557 0.563 
6 Impurity 2 1 1 2 1.986±0.005 99.317±0.225 0.227 
7 150% Eptifibatide 150 225 375 373.040±1.243 99.477±0.331 0.333 
8 Impurity 1 1 1.5 2.5 2.478±0.006 99.107±0.227 0.229 
9 Impurity 2 1 1.5 2.5 2.463±0.003 98.533±0.129 0.130 
*Values given in table are the average±standard deviation for three replicate experiments 
 
 
Fig. 7: Acid degradation chromatogram of Eptifibatide 
 
The % degradation of Eptifibatide in all the stress conditions was 
calculated by comparing the results observed in stress study with 
standard. The % degradation was very high in the acidic degradation 
study. In this condition, the drug was found to be degraded up to 
9.82 % and four additional degradation products were observed at a 
retention time of 1.81, 4.05, 5.55 and 12.03 min [fig. 7]. In base 
degradation study, the drug was found to be degraded up to 8.12 % 
and three additional peaks at a retention time of 2.20, 6.06 and 9.15 
min [fig. 8]. The low % degradation with high stability of Eptifibatide 
was observed in oxidative degradation. In this two additional peak 
was detected at a retention time of 1.35 and 4.68 min and the % 
degradation was found to be 4.05 [fig. 9]. In photolytic degradation, 
the % degradation of Eptifibatide was found to be 9.68 and three 
additional degradation products were detected at a retention time of 
3.58, 3.80 and 9.91 min along with two impurities (1 and 2) in the 
study [fig. 10]. In the thermal degradation study, the % degradation 
was found to be 5.02 and in this condition, three additional 
degradation products were observed at a retention time of 2.75, 6.68 
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and 11.90 min [fig. 11]. In all the degradation condition, standard drug 
Eptifibatide was detected along with both the impurities studied and 
the degradation products were successfully separated in the optimised 
conditions and there is no change in retention time of the Eptifibatide, 
imp 1 and 2. Hence the method can separate and quantify the potential 
impurities in Eptifibatide. 
 
 
Fig. 8: Base degradation chromatogram of Eptifibatide 
 
 
Fig. 9: Oxidative degradation chromatogram of Eptifibatide 
 
 
Fig. 10: Photolytic degradation chromatogram of Eptifibatide 
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Fig. 11: Thermal degradation chromatogram of Eptifibatide 
 
The % drug and impurity content was calculated using the peak area 
values observed for the formulation sample solution and compared 
with standard calibration results. The % assay was found to be 
98.63, 0.41 and 0.27 % of Eptifibatide, impurity 1 and 2, 
respectively. In the formulation chromatogram there is no other 
chromatographic detection of other impurities and formulation 
excipients detected. Hence the developed method was found to be 
suitable for the quantification of Eptifibatide and can separate and 
analyse impurities 1 and 2.  
DISCUSSION 
The present work aimed to develop a simple HPLC method for the 
separation and quantification of related impurities of Eptifibatide in 
injection formulations. The optimized separation of Eptifibatide and 
its 1 and 2 was achieved on Phenomenex Luna C18 column (250 
mm×4.6 mm; 5µ id) as stationary phase, methanol and phosphate 
buffer at pH 6.4 in the ratio of 65:45 (v/v) as mobile phase at a flow 
rate of 1.0 ml/min, UV detection was carried at the wavelength of 
236 nm and the analysis was completed with a run time of 15 min. 
The method developed for the separation and quantification of 
Eptifibatide and its 1 and 2 impurities obeys the system suitability 
parameters like RRF, RRT, tail factor and number of theoretical 
plates. The formulation excipients did not interfere the separation of 
Eptifibatide and its impurities 1and2 and proves that the method is 
specific and suitable.  
The calibration curve was found to be linear within the 
concentration range of 75–450 µg/ml for Eptifibatide and 0.5–3 
µg/ml for both impurity 1 and 2 proves that the method can detect 
the impurities at the lowest concentrations. The % RSD of precision 
studies, ruggedness and the % change in robustness study was 
found to be within the acceptable limit of less than 2 confirms that 
the method is rugged, precise and robust. The method can effectively 
separate the impurities and a stress degradation product of 
Eptifibatide proves that the method is stable.  
The literature survey reveals that there is only one analytical method 
reported by Marie et al., 2012 [12] for the analysis of and its 
impurities. The reported method based on the analysis of Eptifibatide 
and its impurities by Ultra-Performance Liquid Chromatography 
(UPLC) which is cost effective, and less available technique. Hence the 
method developed was found to be the best choice for the routine 
analysis of Eptifibatide and its impurities in formulations.  
CONCLUSION 
A novel stability-indicating RP-HPLC method was developed for the 
separation, identification and quantification of Eptifibatide and its 
impurities 1 and 2. The proposed method achieves satisfactory 
separation of Eptifibatide from impurities and the degradation 
products with extended linear range, high recoveries and rapid 
analysis time. The proposed method ensured the accurate 
determination of Eptifibatide and its impurities in pharmaceutical 
formulations. Hence the method is simple, convenient and suitable 
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